Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group*

Rossella E. Nappi, Nicoletta Biglia, Angelo Cagnacci, Costantino Di Carlo, Stefano Luisi, Anna Maria Paoletti

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Vulvovaginal atrophy (VVA) is a chronic disorder that commonly occurs in postmenopausal women, whose symptoms are recognized among the most frequent and bothersome symptoms associated with menopause. The principal therapeutic goal in managing VVA is to relieve symptoms as well as to restore the vaginal environment to a healthy state. However, despite its high prevalence and negative impact on quality of life, VVA is underreported by women, underrecognized by gynecologists, and therefore, undertreated. In the light of the new development of treatment options for VVA, we here provide an updated expert opinion on the management of VVA. In particular, we strongly recommend that HCPs proactively start an open discussion with their postmenopausal patients about urogenital symptoms. Treatment should be started as early as the first symptoms of VVA occur and should be maintained over time, due to the chronicity of the conditions. Many treatment options are now available and therapy should be individualized, taking the woman’s preference in consideration.

Original languageEnglish
Pages (from-to)602-606
Number of pages5
JournalGynecological Endocrinology
Volume32
Issue number8
DOIs
Publication statusPublished - Aug 2 2016

Fingerprint

Expert Testimony
Atrophy
Therapeutics
Menopause
Quality of Life

Keywords

  • Diagnosis
  • expert opinion
  • management
  • vulvovaginal atrophy
  • VVA

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Obstetrics and Gynaecology

Cite this

Diagnosis and management of symptoms associated with vulvovaginal atrophy : expert opinion on behalf of the Italian VVA study group*. / Nappi, Rossella E.; Biglia, Nicoletta; Cagnacci, Angelo; Di Carlo, Costantino; Luisi, Stefano; Paoletti, Anna Maria.

In: Gynecological Endocrinology, Vol. 32, No. 8, 02.08.2016, p. 602-606.

Research output: Contribution to journalReview article

Nappi, Rossella E. ; Biglia, Nicoletta ; Cagnacci, Angelo ; Di Carlo, Costantino ; Luisi, Stefano ; Paoletti, Anna Maria. / Diagnosis and management of symptoms associated with vulvovaginal atrophy : expert opinion on behalf of the Italian VVA study group*. In: Gynecological Endocrinology. 2016 ; Vol. 32, No. 8. pp. 602-606.
@article{c688ad6726434ea298949fa9d16c067e,
title = "Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group*",
abstract = "Vulvovaginal atrophy (VVA) is a chronic disorder that commonly occurs in postmenopausal women, whose symptoms are recognized among the most frequent and bothersome symptoms associated with menopause. The principal therapeutic goal in managing VVA is to relieve symptoms as well as to restore the vaginal environment to a healthy state. However, despite its high prevalence and negative impact on quality of life, VVA is underreported by women, underrecognized by gynecologists, and therefore, undertreated. In the light of the new development of treatment options for VVA, we here provide an updated expert opinion on the management of VVA. In particular, we strongly recommend that HCPs proactively start an open discussion with their postmenopausal patients about urogenital symptoms. Treatment should be started as early as the first symptoms of VVA occur and should be maintained over time, due to the chronicity of the conditions. Many treatment options are now available and therapy should be individualized, taking the woman’s preference in consideration.",
keywords = "Diagnosis, expert opinion, management, vulvovaginal atrophy, VVA",
author = "Nappi, {Rossella E.} and Nicoletta Biglia and Angelo Cagnacci and {Di Carlo}, Costantino and Stefano Luisi and Paoletti, {Anna Maria}",
year = "2016",
month = "8",
day = "2",
doi = "10.1080/09513590.2016.1183627",
language = "English",
volume = "32",
pages = "602--606",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Diagnosis and management of symptoms associated with vulvovaginal atrophy

T2 - expert opinion on behalf of the Italian VVA study group*

AU - Nappi, Rossella E.

AU - Biglia, Nicoletta

AU - Cagnacci, Angelo

AU - Di Carlo, Costantino

AU - Luisi, Stefano

AU - Paoletti, Anna Maria

PY - 2016/8/2

Y1 - 2016/8/2

N2 - Vulvovaginal atrophy (VVA) is a chronic disorder that commonly occurs in postmenopausal women, whose symptoms are recognized among the most frequent and bothersome symptoms associated with menopause. The principal therapeutic goal in managing VVA is to relieve symptoms as well as to restore the vaginal environment to a healthy state. However, despite its high prevalence and negative impact on quality of life, VVA is underreported by women, underrecognized by gynecologists, and therefore, undertreated. In the light of the new development of treatment options for VVA, we here provide an updated expert opinion on the management of VVA. In particular, we strongly recommend that HCPs proactively start an open discussion with their postmenopausal patients about urogenital symptoms. Treatment should be started as early as the first symptoms of VVA occur and should be maintained over time, due to the chronicity of the conditions. Many treatment options are now available and therapy should be individualized, taking the woman’s preference in consideration.

AB - Vulvovaginal atrophy (VVA) is a chronic disorder that commonly occurs in postmenopausal women, whose symptoms are recognized among the most frequent and bothersome symptoms associated with menopause. The principal therapeutic goal in managing VVA is to relieve symptoms as well as to restore the vaginal environment to a healthy state. However, despite its high prevalence and negative impact on quality of life, VVA is underreported by women, underrecognized by gynecologists, and therefore, undertreated. In the light of the new development of treatment options for VVA, we here provide an updated expert opinion on the management of VVA. In particular, we strongly recommend that HCPs proactively start an open discussion with their postmenopausal patients about urogenital symptoms. Treatment should be started as early as the first symptoms of VVA occur and should be maintained over time, due to the chronicity of the conditions. Many treatment options are now available and therapy should be individualized, taking the woman’s preference in consideration.

KW - Diagnosis

KW - expert opinion

KW - management

KW - vulvovaginal atrophy

KW - VVA

UR - http://www.scopus.com/inward/record.url?scp=84995555396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995555396&partnerID=8YFLogxK

U2 - 10.1080/09513590.2016.1183627

DO - 10.1080/09513590.2016.1183627

M3 - Review article

AN - SCOPUS:84995555396

VL - 32

SP - 602

EP - 606

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 8

ER -